News | Drug-Eluting Balloons | December 06, 2016

Spectranetics Receives CE Mark for Stellarex 0.014-inch Drug-Coated Balloon

Device provides additional treatment option for small vessels, below-the-knee disease and challenging critical limb ischemia

Spectranetics, Stellarex 0.014-inch DCB, CE Mark

December 6, 2016 — The Spectranetics Corp. announced in late November that its Stellarex 0.014-inch drug-coated angioplasty balloon (DCB) has received the CE mark. The device is designed to treat small vessels, below-the-knee disease and challenging critical limb ischemia (CLI) in patients. 

The combination of the currently available Stellarex 0.035-inch and the new 0.014-inch line available in Europe expands Spectranetics’ comprehensive portfolio of next-generation DCBs to treat complex disease states across the lower extremities.

CLI afflicts over 3 million people in the United States and Europe. The critical unmet need of this complex patient population is inhibition of restenosis, which commonly occurs within three to six months of treatment and can lead to high rates of non-wound healing, re-intervention and amputation.

"Now available on a 0.014-inch balloon platform, Stellarex represents a latest-generation DCB backed by compelling evidence in the fem-pop arteries. It holds strong promise to deliver safety and efficacy in the notoriously challenging infrapopliteal district,” said Prof. Dierk Scheinert of Universitätsklinikum in Leipzig, Germany.

For more information: www.spectranetics.com

Related Content

Cardiovascular Systems Expands Product Portfolio for Peripheral and Coronary Interventions
News | Balloon Catheter | January 24, 2018
Cardiovascular Systems Inc. recently announced two new partnerships broadening the company’s product portfolio. CSI is...
Abbott recalls its NC Balloon catheters
News | Balloon Catheter | May 22, 2017
May 22, 2017 — Abbott Vascular has initiated a voluntary recall of specific lots of three catheters due to 19 reports
Videos | Balloon Catheter | November 16, 2016
A discussion with Todd Brinton, M.D., about the newly FDA-cleared Shockwave Medical Lithoplasty System, at the Transc
NuCryo Vascular, Next Generation Cryoplasty Inflation Device, PolarCath Balloon Dilatation System

PolarCath Balloon Dilatation System image courtesy of NuCryo Vascular

Technology | Balloon Catheter | March 28, 2016
NuCryo Vascular LLC announced the launch of the Next Generation Cryoplasty Inflation device. The device received U.S....
NuCryo Vascular, FDA clearance, next-gen, PolarCath System, cryoplasty inflation device
Technology | Balloon Catheter | January 12, 2016
NuCryo Vascular LLC announced that they have received U.S. Food and Drug Administration (FDA) 510(k) clearance on the...
Videos | Balloon Catheter | October 30, 2015
Todd Brinton, M.D., clinical associate professor and consulting associate professor of bioengineering at Stanford Uni
Overlay Init